Clinical Trials Browser

Terminated × INDUSTRY × Thyroid Carcinoma, Anaplastic × Clear all

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Phase 1 Terminated

5 enrolled

DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Phase 1/2 Terminated

19 enrolled 13 charts

EndocrineHead & Neck

Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02657369 2019-10-15

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Phase 2 Terminated

34 enrolled 13 charts

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT00507429 2014-06-09

FACT

Phase 2/3 Terminated

80 enrolled 10 charts

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Clinical Trials

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

FACT